Filing a Depo-Provera lawsuit involves choosing an attorney, gathering medical and use records, and having your case filed in the right court before the statute of limitations runs. This guide walks through the steps.
If you've used Depo-Provera and have been diagnosed with a meningioma, you may be considering filing a lawsuit. Understanding how to file a Depo-Provera lawsuit can help you navigate the legal process and determine whether pursuing a claim makes sense for your situation. This guide will explain the steps involved in filing a lawsuit, what to expect during the process, and how to get started.
Recent research has revealed a connection between long-term Depo-Provera use and the development of meningiomas, tumors that form on the protective layers surrounding the brain and spinal cord. A landmark French study found that women who used high-dose progestogen medications like Depo-Provera for extended periods faced significantly elevated risks of developing these tumors. As litigation develops, understanding the process of filing a lawsuit is important for women who may have valid claims.
Pharmaceutical products and medical research documents
Understanding Your Potential Claim
Before filing a Depo-Provera lawsuit, it's important to understand whether you may have a valid claim. Several factors may affect your eligibility, including the duration of your Depo-Provera use, when you were diagnosed with a meningioma, and the connection between your medication use and your diagnosis.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
Research suggests that the risk of developing meningiomas increases with the duration of Depo-Provera use. Women who used the medication for extended periods, particularly five or more years, may face significantly higher risks. The French study found that women who used high-dose progestogen medications for more than a year had a significantly elevated risk, with some groups facing risks more than five times higher than non-users.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
If you've used Depo-Provera for an extended period and have been diagnosed with a meningioma, you may want to learn more about Depo-Provera lawsuit information and your potential rights. A case review can help determine whether you may have a valid claim before you begin the process of filing a lawsuit.
If you used Depo-Provera and were diagnosed with a brain tumor, you may have legal options.
Free, confidential Depo-Provera case review. Find out if you qualify.
Get a free Depo-Provera case reviewThe First Step: Case Review
The first step in filing a Depo-Provera lawsuit is typically a case review, which is an initial evaluation to determine whether you may have a valid legal claim. This process is confidential, free, and does not create any obligation on your part.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
Initial Consultation: The process typically begins with a conversation about your Depo-Provera use history and medical diagnosis. You'll be asked about when you started using Depo-Provera, how long you used it, when you received your meningioma diagnosis, and what symptoms you've experienced. This information helps determine whether your situation may qualify for a lawsuit.
Medical Records Review: If you decide to proceed, medical records related to your meningioma diagnosis and treatment may be reviewed. This helps establish the connection between your medication use and your condition. You may also be asked about your Depo-Provera injection history and any documentation you have.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
Eligibility Assessment: Based on the information gathered, an assessment will be made about whether you may qualify to pursue a claim. Factors considered include the duration of your Depo-Provera use, the timing of your diagnosis, and how your case fits within the broader litigation.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
Women who developed meningiomas after Depo-Provera injections may qualify for compensation.
No-cost evaluation for women who used Depo-Provera and developed a brain tumor.
Check your Depo-Provera eligibilityThe National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
Next Steps: If you may qualify, you'll be informed about the next steps in the legal process. This might include connecting you with an independent law firm that handles Depo-Provera cases. If you don't qualify, you'll receive an explanation of why.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
No Upfront Costs: Case reviews are conducted at no cost to you. If you qualify and choose to proceed with a case, most attorneys work on a contingency fee basis, meaning they only receive payment if your case is successful. To understand more about how mass tort cases work, you may find our guide on understanding mass tort litigation helpful.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
The case review process is designed to be straightforward and respectful of your situation. The goal is to help you understand your options and determine whether pursuing legal action makes sense for your circumstances. If you're ready to begin, you can contact us for a free case review.
Legal documents and research papers representing ongoing litigation
A confidential case review can help you understand your Depo-Provera legal options.
No obligation. Understand your Depo-Provera legal options at no cost.
Request a free Depo-Provera evaluationWhat Is Depo-Provera?
Depo-Provera is an injectable contraceptive medication that contains the hormone medroxyprogesterone acetate. The medication is administered as an injection every three months to prevent pregnancy. It has been used by millions of women worldwide since its approval by the FDA in 1992.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
The medication works by preventing ovulation and thickening cervical mucus to block sperm. While effective for birth control, emerging research has raised concerns about potential long-term health risks, particularly related to brain tumor development. Many women have used Depo-Provera for extended periods, sometimes for years or even decades, which may have contributed to the increased risk observed in recent studies.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
Don't wait on your Depo-Provera claim—statutes of limitations may apply.
Get a free Depo-Provera case review and learn whether you may qualify.
See if you qualify for a Depo-Provera lawsuitDepo-Provera injections are typically administered by healthcare providers into the muscle of the arm or buttock. Each injection releases the hormone slowly over time, maintaining contraceptive effectiveness for approximately 12 to 14 weeks. The cumulative exposure from repeated injections over many years may be a factor in the increased meningioma risk observed in long-term users.
The Legal Process: What to Expect
If you decide to file a Depo-Provera lawsuit, understanding what to expect during the legal process can help you prepare and make informed decisions. The process typically involves several stages that can span several years.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
Filing the Lawsuit: If you qualify and choose to proceed, an attorney will file a lawsuit on your behalf. The lawsuit will detail your specific injuries, medical history, and damages. Even though your case may eventually be consolidated with others, it remains your individual claim. The lawsuit will be filed in an appropriate court, which may be federal or state court depending on various factors.
If you used Depo-Provera and were diagnosed with a brain tumor, you may have legal options.
Free, confidential Depo-Provera case review. Find out if you qualify.
Get a free Depo-Provera case reviewA 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
Discovery Phase: After the lawsuit is filed, both sides gather evidence during the discovery phase. This process can be extensive and may include reviewing millions of pages of company documents, taking depositions of company executives and medical professionals, examining internal company communications, consulting with expert witnesses, and gathering medical records and other evidence.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
Consolidation: In many mass tort cases, individual lawsuits are filed in federal courts across the country. The Judicial Panel on Multidistrict Litigation (JPML) may decide to consolidate these cases into an MDL, transferring them to a single federal court for coordinated pretrial proceedings. This system helps streamline the discovery process and ensures consistent rulings on common legal issues.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
Women who developed meningiomas after Depo-Provera injections may qualify for compensation.
No-cost evaluation for women who used Depo-Provera and developed a brain tumor.
Check your Depo-Provera eligibilityBellwether Trials: Bellwether trials are test cases selected to go before juries. These trials help both sides understand how juries might view the evidence and what damages might be appropriate. The outcomes of bellwether trials don't directly determine the outcome of other cases, but they provide valuable information that often leads to settlement negotiations.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
Settlement or Trial: After bellwether trials, the parties often enter into settlement negotiations. Many mass tort cases are resolved through settlement programs that provide compensation to eligible plaintiffs. If settlement negotiations don't succeed, individual cases may proceed to trial, where each plaintiff's case is tried individually.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
If you've used Depo-Provera for an extended period and have been diagnosed with a meningioma, see if you qualify for a free case review to determine whether you may have a valid claim. You can learn more about Depo-Provera lawsuit information and your potential rights.
Important Factors in Filing a Lawsuit
Several factors may affect your ability to file a Depo-Provera lawsuit and the strength of your potential claim. Understanding these factors can help you make informed decisions about pursuing legal action.
A confidential case review can help you understand your Depo-Provera legal options.
No obligation. Understand your Depo-Provera legal options at no cost.
Request a free Depo-Provera evaluationA 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
Duration of Use: Research suggests that the risk of developing meningiomas increases with the duration of Depo-Provera use. Women who used the medication for extended periods, particularly five or more years, may have stronger claims. The French study found that women who used high-dose progestogen medications for more than a year had a significantly elevated risk.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
Timing of Diagnosis: The timing of your meningioma diagnosis relative to your Depo-Provera use may be relevant. Cases typically involve women who were diagnosed after using the medication, particularly those who used it for extended periods. The connection between medication use and diagnosis timing is an important factor in evaluating potential claims.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
Medical Documentation: Having medical records that document both your Depo-Provera use and your meningioma diagnosis can be important for establishing your claim. These records help establish the connection between your medication use and your condition, which is necessary for pursuing a legal claim.
Don't wait on your Depo-Provera claim—statutes of limitations may apply.
Get a free Depo-Provera case review and learn whether you may qualify.
See if you qualify for a Depo-Provera lawsuitAccording to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
Statutes of Limitations: Statutes of limitations set deadlines for filing lawsuits. These deadlines vary by state and depend on factors such as when you discovered your injury and when you were diagnosed. Missing these deadlines can permanently bar you from pursuing compensation, so it's important to act promptly if you believe you may have a claim.
Evidence and documents in legal proceedings
Who May Be Affected
Women who used Depo-Provera for extended periods may be at increased risk of developing meningiomas and may be eligible to file lawsuits. Research suggests that the risk increases with the duration of use. Women who used the medication for one to four years may face a moderate increase in risk, while those who used it for five or more years may face significantly higher risks. Women who used it for ten or more years may face the highest risks.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
The French study found that women who used high-dose progestogen medications for more than a year had a significantly elevated risk, with some groups facing risks more than five times higher than non-users. Women who have been diagnosed with meningiomas after using Depo-Provera should consider having their situation evaluated to determine whether they may have a valid legal claim and whether filing a lawsuit makes sense for their circumstances.
If you used Depo-Provera and were diagnosed with a brain tumor, you may have legal options.
Free, confidential Depo-Provera case review. Find out if you qualify.
Get a free Depo-Provera case reviewThe National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
If you've used Depo-Provera for an extended period and have been diagnosed with a meningioma, you may want to learn more about Depo-Provera lawsuit information and your potential rights.
Current Status of Litigation
Litigation related to Depo-Provera and meningiomas is developing as more women learn about the potential connection between their medication use and brain tumor diagnosis. Cases are being filed alleging that manufacturers knew about the risks but failed to adequately warn patients and healthcare providers.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
The litigation is in early stages, with cases being filed in various courts. As more scientific evidence emerges and more women come forward, the litigation may develop into consolidated proceedings similar to other pharmaceutical mass tort cases. Scientific evidence continues to accumulate linking progestogen exposure to meningioma development, and this evidence may support legal claims that manufacturers had an obligation to warn about these risks but failed to do so adequately.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
Women who developed meningiomas after Depo-Provera injections may qualify for compensation.
No-cost evaluation for women who used Depo-Provera and developed a brain tumor.
Check your Depo-Provera eligibilityEvidence suggests that the risks associated with progestogen exposure were known for years before adequate warnings were provided. Pharmaceutical companies have a legal obligation to warn patients and healthcare providers about known risks. If you've used Depo-Provera for an extended period and developed a meningioma, you may be entitled to compensation for medical expenses, lost wages, pain and suffering, future medical care, and reduced quality of life.
What a Case Review Involves
A case review is an initial evaluation to determine whether you may have a valid legal claim related to Depo-Provera use and meningioma development. This process is confidential, free, and does not create any obligation on your part.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
Initial Consultation: The process typically begins with a conversation about your Depo-Provera use history and medical diagnosis. You'll be asked about when you started using Depo-Provera, how long you used it, when you received your meningioma diagnosis, and what symptoms you've experienced. This information helps determine whether your situation may qualify for filing a lawsuit.
Medical Records Review: If you decide to proceed, medical records related to your meningioma diagnosis and treatment may be reviewed. This helps establish the connection between your medication use and your condition. You may also be asked about your Depo-Provera injection history and any documentation you have.
Eligibility Assessment: Based on the information gathered, an assessment will be made about whether you may qualify to pursue a claim. Factors considered include the duration of your Depo-Provera use, the timing of your diagnosis, and how your case fits within the broader litigation.
A confidential case review can help you understand your Depo-Provera legal options.
No obligation. Understand your Depo-Provera legal options at no cost.
Request a free Depo-Provera evaluationAccording to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
Next Steps: If you may qualify, you'll be informed about the next steps in the legal process, including how to file a Depo-Provera lawsuit. This might include connecting you with an independent law firm that handles Depo-Provera cases. If you don't qualify, you'll receive an explanation of why.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
No Upfront Costs: Case reviews are conducted at no cost to you. If you qualify and choose to proceed with filing a lawsuit, most attorneys work on a contingency fee basis, meaning they only receive payment if your case is successful. To understand more about how mass tort cases work, you may find our guide on understanding mass tort litigation helpful.
The case review process is designed to be straightforward and respectful of your situation. The goal is to help you understand your options and determine whether filing a Depo-Provera lawsuit makes sense for your circumstances. If you're ready to begin, you can contact us for a free case review.
Filing is a team process
Choosing counsel, completing intake, and meeting court deadlines happen in sequence. Start with a free review before paying filing fees or signing retainers you do not understand.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
Don't wait on your Depo-Provera claim—statutes of limitations may apply.
Get a free Depo-Provera case review and learn whether you may qualify.
See if you qualify for a Depo-Provera lawsuitScientific Evidence: While research suggests a link between Depo-Provera and meningiomas, scientific evidence continues to evolve. Courts will evaluate this evidence, and outcomes may depend on how juries and judges interpret the available research.
Litigation Timeline: Mass tort litigation typically takes several years to resolve. Cases may proceed through discovery, expert witness preparation, and potentially trials or settlement negotiations. The timeline for your specific case depends on many factors beyond your control.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
See if you qualify for a free case review to learn more about your potential rights and options. You can also learn more about Depo-Provera lawsuit information and your potential rights.
Important Disclaimers
Understanding how to file a Depo-Provera lawsuit is an important first step for women who have used the medication and been diagnosed with meningiomas. If you've used Depo-Provera for an extended period and have been diagnosed with a meningioma, understanding your legal rights and options is important.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
Multidistrict litigation coordinates pretrial work but your case remains individual in most mass torts. Ask referred counsel how MDL orders may affect your timeline.
If you used Depo-Provera and were diagnosed with a brain tumor, you may have legal options.
Free, confidential Depo-Provera case review. Find out if you qualify.
Get a free Depo-Provera case reviewTop Tier Legal, LLC is not a law firm and does not provide legal advice. This content is for informational purposes only. Submitting information does not create an attorney-client relationship. If you qualify, Top Tier Legal, LLC may connect you with an independent law firm. Past results do not guarantee future outcomes.
